Mixed Trial Results For AstraZeneca And Rigel

AstraZeneca (NYSE: AZN) and Rigel Pharmaceuticals Inc. (Nasdaq: RIGL) reported mixed results from a late stage clinical trial of their rheumatoid arthritis treatment fostamatinib. Shares of AstraZeneca edged up 24 cents to $50.37 while Rigel Pharmaceuticals stock plummeted $2.79 to $4.74.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here